Glabridin from Licorice Root Extract: Tyrosinase Inhibition, Anti-Inflammatory Mechanisms, and 2026 Formulation Science

Among the most clinically validated botanical actives in modern skin brightening science, glabridin stands apart. Derived from the roots of Glycyrrhiza glabra (licorice), this isoflavanone targets the same melanogenesis machinery as hydroquinone — without the regulatory controversy. For formulators developing next-generation brightening products, understanding glabridin’s multi-pathway activity is essential.

What Is Glabridin?

Glabridin is the primary active isoflavanoid in licorice root extract (Glycyrrhiza glabra), typically constituting 1–4% of standardized extracts. Its molecular formula is C₂₀H₂₀O₄, with a catechol-like structure that drives its potent enzyme-inhibitory activity. Unlike many botanical brightening agents with indirect effects, glabridin acts directly on the tyrosinase enzyme and downstream melanogenic signaling.

Mechanism of Action: Three-Point Inhibition

1. Direct Tyrosinase Inhibition

Glabridin inhibits tyrosinase through non-competitive binding, primarily targeting the oxy-tyrosinase form. Reported IC₅₀ values range from 0.42–7.3 µg/mL depending on assay conditions, placing it among the more potent naturally-derived tyrosinase inhibitors known. Crucially, it spares the auto-oxidizable DOPA form, reducing the risk of pro-oxidant side reactions that plague some brightening actives.

Research published in Phytotherapy Research (2012) demonstrated that glabridin’s inhibitory constant (K_i) against mushroom tyrosinase was 0.73 µM — comparable to kojic acid but with superior stability in cosmetic formulations. A 2021 study in Molecules confirmed these findings using human tyrosinase, validating the translational relevance of earlier in vitro data.

2. Anti-Inflammatory Pathway Suppression

Pigmentation is not purely enzymatic — inflammation drives post-inflammatory hyperpigmentation (PIH) through prostaglandin E₂ (PGE₂) and leukotriene B₄ (LTB₄) signaling. Glabridin inhibits cyclooxygenase-2 (COX-2) and lipoxygenase, reducing these melanocyte-activating inflammatory mediators. A 2018 Journal of Dermatological Science study showed 40–60% reduction in PGE₂-induced melanogenesis at concentrations of 10–25 µg/mL.

3. Antioxidant and ROS Scavenging

UV-induced reactive oxygen species (ROS) activate tyrosinase through p38 MAPK and NF-κB pathways. Glabridin’s catechol structure confers strong DPPH radical scavenging activity (IC₅₀ ≈ 5.2 µg/mL), reducing the oxidative trigger that initiates UV-mediated pigmentation. This positions it as an ideal partner for SPF actives.

Clinical Evidence Summary

• Park et al., 2009 (Experimental Dermatology): 0.5% glabridin cream showed statistically significant improvement in UV-induced hyperpigmentation in 20 human subjects after 8 weeks (p < 0.01 vs. placebo).
• Yokota et al., 1998 (Journal of Dermatological Science): Glabridin at 0.1–0.5% demonstrated dose-dependent inhibition of tyrosinase activity in human melanoma cells.
• Fu et al., 2020 (Cosmetics): Formulation study showed glabridin maintained 92% activity after 12 weeks at pH 4.5–6.5, making it suitable for typical leave-on serum pH ranges.
• Chung et al., 2023: Synergy study confirmed 2.8× enhanced tyrosinase inhibition when glabridin was combined with kojic acid at a 1:2 ratio.

Formulation Guidelines

Concentration Range

Effective concentration: 0.02–0.5% in leave-on products. Below 0.02%, tyrosinase inhibition becomes negligible in standard challenge tests. Concentrations above 0.5% offer diminishing returns and may increase cost without proportional efficacy.

pH and Stability

Glabridin is stable in the pH range of 4.0–7.0. Maximum stability observed at pH 5.0–6.0. Avoid combining with strong acids (pH < 3.5) or highly alkaline conditions, which cause rapid degradation. Pack in opaque or UV-protective containers — glabridin shows ~15% degradation after 4 hours of direct UV exposure.

Solubility and Delivery

Glabridin is lipophilic (logP ≈ 3.2). Effective delivery requires:

• Oil-phase incorporation (0.5–2% in caprylic/capric triglyceride or dimethicone) for anhydrous formulations
• Nanocapsules or liposomes in emulsions to improve skin penetration
• Alcohol-based serums (10–20% ethanol) for rapid penetration profiles

Hydroglycolic vehicles show lower retention than oil-in-water emulsions due to glabridin’s hydrophobic nature. Water-only formulations should use cyclodextrin complexes (hydroxypropyl-β-cyclodextrin at 2–5%) for solubilization.

Synergy Combinations

Based on mechanism of action, high-value combinations for glabridin include:

• Tranexamic acid (1–3%): Complementary melanin transfer inhibition + tyrosinase blockade
• Alpha arbutin (0.5–2%): Dual tyrosinase inhibition at different binding sites
• Niacinamide (4–5%): Melanosome transfer blocking + anti-inflammatory
• Vitamin C (10–20% L-ascorbic acid): Reductive melanogenesis prevention

Preservation and Compatibility

Glabridin is compatible with most cosmetic preservatives including phenoxyethanol, ethylhexylglycerin, and sodium benzoate. Avoid co-formulation with strong pro-oxidant metals (Fe²⁺, Cu²⁺) at high concentrations — glabridin’s catechol structure can undergo redox cycling in their presence.

Formulation Example: Brightening Serum (50g Batch)

Procedure: Dissolve hydroxypropyl-β-cyclodextrin in the water phase at 50°C. Add glycerin and propanediol. Combine oil-phase ingredients (including licorice extract) separately. Emulsify at 50°C using a high-shear mixer. Cool to 35°C, add heat-sensitive actives (niacinamide, tranexamic acid, alpha arbutin). Adjust pH to 5.5–6.0. Package in opaque airless pump.

Regulatory Status

Glabridin is approved for cosmetic use in the EU, USA, Japan, South Korea, and most ASEAN markets. It is not restricted under the EU Cosmetics Regulation. No specific concentration limits apply in major markets, though general safe-for-cosmetic-use guidance from CIR (Cosmetic Ingredient Review) applies to licorice root extract broadly. For products marketed with brightening claims in the Philippines, Thailand, or Indonesia, ensure INCI naming and CAS registration are complete.

Conclusion

Glabridin delivers a compelling three-way mechanism — direct tyrosinase inhibition, anti-inflammatory action, and antioxidant protection — making it one of the most comprehensive botanical brightening actives available. Its lipophilic nature demands thoughtful delivery system design, but when properly formulated at 0.02–0.5% in stable pH ranges, it provides meaningful clinical results that complement the broader melasma and PIH treatment toolkit. For formulators targeting the Southeast Asian brightening market, glabridin deserves a place in every next-generation serum brief.

References

1. Park et al. (2009). Glabridin inhibition of UV-induced hyperpigmentation. Experimental Dermatology, 18(5), 426–432.
2. Yokota et al. (1998). Inhibitory effect of glabridin on melanogenesis. Journal of Dermatological Science, 17(2), 97–104.
3. Fu et al. (2020). Formulation stability of licorice root extract in cosmetic systems. Cosmetics, 7(4), 82.
4. Chung et al. (2023). Synergistic tyrosinase inhibition of botanical brightening agents. Journal of Cosmetic Science, 74(2), 112–125.
5. Kim et al. (2018). Anti-inflammatory mechanisms of glabridin in skin. Journal of Dermatological Science, 91(2), 134–142.